Contemporary external beam radiotherapy boost or high dose-rate brachytherapy boost for cervical cancer : a propensity-score-matched, nationwide, population-based cohort study
AJCR Copyright © 2021..
To estimate the survival effects of contemporary external beam radiotherapy (EBRT) boost modalities (intensity-modulated radiation therapy or volumetric modulated arc therapy) and high dose-rate brachytherapy (HDR-BT) boost in patients with cervical cancer (CC). Patients who had been diagnosed as having CC were recruited from the Taiwan Cancer Registry Database. Propensity score matching was performed, and Cox proportional-hazards model curves were used to analyze the all-cause mortality of patients who received standard whole-pelvis irradiation with different boost modalities. The matching process yielded a final cohort of 1,630 patients (815 in the EBRT boost and HDR-BT boost groups, respectively) eligible for further analysis. The multivariate Cox regression analyses indicated that the adjusted hazard ratio (95% confidence intervals) for EBRT boost compared with HDR-BT boost was 1.62 (1.43-1.84). Multivariable analysis revealed that the independent poor prognostic factors of all-cause mortality among patients with CC were adenocarcinoma, no chemotherapy, Charlson comorbidity index score ≥ 1, age ≥ 60 years, and advanced International Federation of Gynecology and Obstetrics stage. HDR-BT boost may be more beneficial than contemporary EBRT boost in selected patients with CC.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
American journal of cancer research - 11(2021), 4 vom: 09., Seite 1719-1732 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Jiaqiang [VerfasserIn] |
|---|
| Themen: |
Boost |
|---|
| Anmerkungen: |
Date Revised 07.05.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM325013284 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325013284 | ||
| 003 | DE-627 | ||
| 005 | 20231225191531.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325013284 | ||
| 035 | |a (NLM)33948385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Jiaqiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Contemporary external beam radiotherapy boost or high dose-rate brachytherapy boost for cervical cancer |b a propensity-score-matched, nationwide, population-based cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 07.05.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJCR Copyright © 2021. | ||
| 520 | |a To estimate the survival effects of contemporary external beam radiotherapy (EBRT) boost modalities (intensity-modulated radiation therapy or volumetric modulated arc therapy) and high dose-rate brachytherapy (HDR-BT) boost in patients with cervical cancer (CC). Patients who had been diagnosed as having CC were recruited from the Taiwan Cancer Registry Database. Propensity score matching was performed, and Cox proportional-hazards model curves were used to analyze the all-cause mortality of patients who received standard whole-pelvis irradiation with different boost modalities. The matching process yielded a final cohort of 1,630 patients (815 in the EBRT boost and HDR-BT boost groups, respectively) eligible for further analysis. The multivariate Cox regression analyses indicated that the adjusted hazard ratio (95% confidence intervals) for EBRT boost compared with HDR-BT boost was 1.62 (1.43-1.84). Multivariable analysis revealed that the independent poor prognostic factors of all-cause mortality among patients with CC were adenocarcinoma, no chemotherapy, Charlson comorbidity index score ≥ 1, age ≥ 60 years, and advanced International Federation of Gynecology and Obstetrics stage. HDR-BT boost may be more beneficial than contemporary EBRT boost in selected patients with CC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cervical cancer | |
| 650 | 4 | |a boost | |
| 650 | 4 | |a brachytherapy | |
| 650 | 4 | |a external beam radiotherapy | |
| 650 | 4 | |a high dose rate | |
| 700 | 1 | |a Sun, Mingyang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ningtao |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Mengrong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yitian |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Han-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ho-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Szu-Yuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of cancer research |d 2011 |g 11(2021), 4 vom: 09., Seite 1719-1732 |w (DE-627)NLM207988722 |x 2156-6976 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:4 |g day:09 |g pages:1719-1732 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 4 |b 09 |h 1719-1732 | ||